cobchb

Property	Value
?:abstract	INTRODUCTION: Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of cancer patients from the LEOSS (Lean European Open Survey on SARS-CoV-2 Infected Patients) registry to determine whether cancer patients are at higher risk. PATIENTS AND METHODS: We retrospectively analyzed a cohort of 435 cancer patients and 2636 non-cancer patients with confirmed SARS-CoV-2 infection, enrolled between March 16 and August 31, 2020. Data on socio-demographics, comorbidities, cancer-related features and infection course were collected. Age-, sex- and comorbidity-adjusted analysis was performed. Primary endpoint was COVID-19-related mortality. RESULTS: In total, 435 cancer patients were included in our analysis. Commonest age category was 76–85 years (36.5%), and 40.5% were female. Solid tumors were seen in 59% and lymphoma and leukemia in 17.5% and 11% of patients. Of these, 54% had an active malignancy, and 22% had recently received anti-cancer treatments. At detection of SARS-CoV-2, the majority (62.5%) presented with mild symptoms. Progression to severe COVID-19 was seen in 55% and ICU admission in 27.5%. COVID-19-related mortality rate was 22.5%. Male sex, advanced age, and active malignancy were associated with higher death rates. Comparing cancer and non-cancer patients, age distribution and comorbidity differed significantly, as did mortality (14% vs 22.5%, p value < 0.001). After adjustments for other risk factors, mortality was comparable. CONCLUSION: Comparing cancer and non-cancer patients, outcome of COVID-19 was comparable after adjusting for age, sex, and comorbidity. However, our results emphasize that cancer patients as a group are at higher risk due to advanced age and pre-existing conditions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00277-020-04328-4.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/67cobchb_hasAnnotation_C0006826> <https://research.tib.eu/covid-19/entity/67cobchb_hasAnnotation_C0023418> <https://research.tib.eu/covid-19/entity/67cobchb_hasAnnotation_C0024299> <https://research.tib.eu/covid-19/entity/67cobchb_hasAnnotation_C0280100> <https://research.tib.eu/covid-19/entity/67cobchb_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/R%C3%BCthrich%2C_Maria_Madeleine%3B_Giessen-Jung%2C_C.%3B_Borgmann%2C_S.%3B_Classen%2C_A._Y.%3B_Dolff%2C_S.%3B_Gr%C3%BCner%2C_B.%3B_Hanses%2C_F.%3B_Isberner%2C_N.%3B_K%C3%B6hler%2C_P.%3B_Lanznaster%2C_J.%3B_Merle%2C_U.%3B_Nadalin%2C_S.%3B_Piepel%2C_C.%3B_Schneider%2C_J.%3B_Schons%2C_M.%3B_Strauss%2C_R.%3B_Tometten%2C_L.%3B_Vehreschild%2C_J._J.%3B_von_Lilienfeld-Toal%2C_M.%3B_Beutel%2C_G.%3B_Wille%2C_K.>
?:doi	<https://research.tib.eu/covid-19/entity/10.1007/s00277-020-04328-4>
?:doi	10.1007/s00277-020-04328-4
?:journal	Ann_Hematol
?:license	cc-by
?:pdf_json_files	document_parses/pdf_json/16561147da1a832bef3c3c82ac57dea3abd31886.json
?:pmc_json_files	document_parses/pmc_json/PMC7648543.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7648543>
?:pmid	<https://research.tib.eu/covid-19/entity/33159569.0>
?:pmid	33159569.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/16561147da1a832bef3c3c82ac57dea3abd31886>
?:source	Medline; PMC
?:title	COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-07

Property

Value

?:abstract

INTRODUCTION: Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of cancer patients from the LEOSS (Lean European Open Survey on SARS-CoV-2 Infected Patients) registry to determine whether cancer patients are at higher risk. PATIENTS AND METHODS: We retrospectively analyzed a cohort of 435 cancer patients and 2636 non-cancer patients with confirmed SARS-CoV-2 infection, enrolled between March 16 and August 31, 2020. Data on socio-demographics, comorbidities, cancer-related features and infection course were collected. Age-, sex- and comorbidity-adjusted analysis was performed. Primary endpoint was COVID-19-related mortality. RESULTS: In total, 435 cancer patients were included in our analysis. Commonest age category was 76–85 years (36.5%), and 40.5% were female. Solid tumors were seen in 59% and lymphoma and leukemia in 17.5% and 11% of patients. Of these, 54% had an active malignancy, and 22% had recently received anti-cancer treatments. At detection of SARS-CoV-2, the majority (62.5%) presented with mild symptoms. Progression to severe COVID-19 was seen in 55% and ICU admission in 27.5%. COVID-19-related mortality rate was 22.5%. Male sex, advanced age, and active malignancy were associated with higher death rates. Comparing cancer and non-cancer patients, age distribution and comorbidity differed significantly, as did mortality (14% vs 22.5%, p value < 0.001). After adjustments for other risk factors, mortality was comparable. CONCLUSION: Comparing cancer and non-cancer patients, outcome of COVID-19 was comparable after adjusting for age, sex, and comorbidity. However, our results emphasize that cancer patients as a group are at higher risk due to advanced age and pre-existing conditions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00277-020-04328-4.

is ?:annotates of